Bayer Hires Counsel To Look At Trasylol Disclosure

Law360, New York (October 16, 2006, 12:00 AM EDT) -- Bayer AG has appointed independent counsel to review the company’s failure to disclose to the U.S. Food and Drug Administration a study that revealed health risks posed by its heart surgery drug, Trasylol.

The company announced Friday that it had retained Fred F. Fielding from Wiley Rein & Fielding LLP to conduct a thorough investigation, and provide recommendations as to how Bayer should proceed.

“Bayer immediately initiated a full investigation into the matter and based on our investigation so far, we believe this was a serious...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.